Objective: This study evaluates the use of multimodal imaging to qualitatively and quantitatively measure tumor progression and bone resorption in a xenotransplanted tumor model of human neuroblastoma. Methods: Human neuroblastoma cells expressing a luciferase reporter gene were injected into the femur of nu/nu mice. Tumor progression with and without zoledronic acid treatment was monitored using radiographs, D-luciferin-induced luminescence, micro-computer tomography (CT) and micro-magnetic resonance imaging (MRI). Results: We observed a gradual increase in D-luciferin-based bioluminescence concomitant with detectable osteolytic lesions. Tumor growth was inhibited (P = 0.003Y0.07) with zoledronic acid treatment. Micro-CT analysis in vivo provided a method to quantify bone loss, and its prevention by zoledronic acid. High-resolution MRI images allowed the observation of tumor cells within the bone marrow cavity, as well as distant metastasis. B one metastasis is a major factor of mortality and morbidity in patients with cancer and is the third most common site of metastasis in cancer patients.
B one metastasis is a major factor of mortality and morbidity in patients with cancer and is the third most common site of metastasis in cancer patients. 1 It is associated with a dramatic increase in bone remodeling which involves activation of bone forming osteoblasts and bone degrading osteoclasts. Such intense remodeling is not unique to cancer and is also observed in non-malignant disorders of the bone like osteoarthritis or osteoporosis. Bone metastases are typically classified into osteoblastic and osteolytic. 2, 3 In osteoblastic metastases, commonly observed in prostate cancers, there is a significant amount of new bone formation as a result of osteoblast stimulation by cancer cells. In osteolytic metastases, seen in myeloma, neuroblastoma, and in cancers of the breast and the thyroid, stimulation of osteoclasts by malignant cells is the dominant feature that leads to the formation of osteolytic lesions. 4 The mechanism by which tumor cells that colonize the bone marrow invade and remodel mineralized bone has been the subject of extensive investigations over the last decade. The emerging concept is that tumor cells express osteoclast activating factors like parathyroid hormone related peptide (PTHrP), which stimulates the expression of the receptor activator of NF-JB ligand (RANKL) by osteoblasts. RANKL then activates RANK expressing osteoclast precursor cells and initiates their proliferation, differentiation and bone degradative activity. 5 Alternatively, tumor cells directly or indirectly via stimulation of bone marrow stromal cells, express osteoclast activating factors such as RANKL, IL(interleukin)-1, IL-6, insulin-like growth factor (IGF-1), tumor necrosis factor (TNF)-> or macrophage colony stimulating factor (M-CSF) which trigger osteoclast activation. 1 Our recent understanding of these processes has led to the identification of several agents that have a potent inhibitory activity on bone metastasis and bone resorption in preclinical models. Among those are bisphosphonates, a family of phosphoric acid-based nitrogen-containing compounds with high binding affinity for the bone matrix that inhibit osteoblasts and osteoclasts by inducing apoptosis. 6 Y 8 More recently, monoclonal antibodies against RANKL have been developed and shown to have excellent antiresorptive activity in premenopausal women. 9 The proteasome inhibitor PS-341 (Bortezomib or Velcade) has been shown to have activity against myeloma by abrogating IL-6 triggered signaling cascades. 2, 10 Several of these inhibitors have shown promising results in clinical trials and some are currently approved by the FDA for clinical use. 11 Interestingly, most of these agents were initially developed to treat bone disease like osteoporosis or osteoarthritis and their potential use as anticancer agents has only been recently explored. 12, 13 The development of animal models to test novel therapeutic agents that can prevent or arrest excessive bone remodeling is critical for the assessment of these agents and to determine their potential value in clinical trials in patients affected with bone disease including malignant bone metastasis.
In our laboratory we have previously reported a murine xenotransplanted model to study bone invasion by human neuroblastoma, the second most common malignancy in children, and a cancer that frequently metastasizes to the bone.
14 Using this model, we have documented that neuroblastoma bone metastasis is primarily a process that involves osteoclast activation. We now have developed and compared several imaging methodologies for their ability to monitor the progression of malignant osteolytic lesions and to quantify the loss of mineralized cortical bone associated with this process. Our data demonstrate that radiographs, bioluminescence,
MATERIALS AND METHODS

Cell Culture
The human neuroblastoma cell line CHLA-255 was derived from a metastatic lesion to the brain of a patient with recurrent neuroblastoma after treatment with intensive nonmyeloablative chemotherapy and 13-cis-retinoic acid. CHLA-255 cells have amplification of MYCN and are highly metastatic when injected intravenously in immunodeficient mice. Cells were cultured in Iscove`s modified Dulbecco`s medium (Bio-Whittaker, Walkersville, MD) containing 20% fetal bovine serum (Omega Scientific Inc., Tarzana, CA), and supplemented with insulin (5 Kg/mL), transferrin (5 Kg/mL), and selenium (5 ng/mL; ITS premix; Fisher Scientific, Pittsburgh, PA); penicillin G (100 units/mL); and streptomycin sulfate (100 Kg/mL; Irvine Scientific, Santa Ana, CA). CHLA-255 cells were transduced using supernatant from a firefly luciferase expressing lentiviral vector producing cells obtained from Dr. D. Kohn (Childrens Hospital Los Angeles, CA). CHLA-255 luc cells were subcloned, and clones that expressed the highest levels of luciferase activity were selected. One high expressing clone (CHLA-255 luc W01) was passaged in vivo by injection into the femur of a nude mouse. CHLA-255 luc W01 cells proliferated at a similar rate when compared to the untransduced parent cells and were used for all experiments described in this paper.
Inoculation of Neuroblastoma Cells in the Femur of Nude Mice
Four to six week-old female BALB/c nu/nu mice were purchased from Harlan Sprague Dawley, (St. Louis, MO). Animal housing, care, and procedures were conducted according to the policies of the Institutional Animal Care and Use Committee at Childrens Hospital Los Angeles. Tumor cells (2 Â 10 5 cells) were directly injected into the femur as described previously.
14 When indicated, mice were treated daily with either subcutaneous injections of sterile solution (0.1 mL) of zoledronic acid (40 Kg/mL) or PBS. Mice were euthanized when they developed large tumors (above 1 cm 3 ) or showed signs of distress.
Bioluminescence Imaging
Mice were anesthetized by inhalation of 1.5% isoflurane-98.5% O 2 (Abbott Laboratories, North Chicago, IL) and intraperitoneally injected with 0.3 mL of D-luciferin (5 mg/mL) in sterile PBS, and bioluminescence imaging with a chargecoupled device (CCD) camera (IVIS, Xenogen, Alameda, CA) was initiated 15 minutes after injection. Bioluminescence images were obtained with a 15 cm field of view (FOV), a binning (resolution) factor of 10, 4/f stop, and open filter. Images were recorded over 5 minutes. Bioluminescence from the region of interest (ROI) was defined manually and included the entire right femur. The data were expressed as photons/s/ cm 2 /steradian. For ex vivo imaging, mice were immediately sacrificed after in vivo imaging and tissues of interest were dissected to be again imaged using the Xenogen IVIS system.
For the experiments on the effect of angle on bioluminescence signal in this model, mice (n = 2) were imaged (30 sec) from 0 to 90 degrees in 15 degree increments starting 13 minutes after luciferin injection with 0 degree measurements taken at 13, 18 and 23 minutes (total experiment was done over 10 minutes). The numerical measurements from the ROI were corrected by normalization to the first 0 degree time point using a two step linear interpolation based on the three 0 degree values.
Radiographs
Anesthetized mice were radiographed using a Faxitron X-ray Instrument (MX-20; Faxitron X-ray Corp., Wheeling, IL). Images were generated using high-resolution mammography films as previously described.
14 Each radiograph was blindly evaluated by one of us (M.D.N.).
. The images were graded using a previously established grading system.
14 Grade 1 represents a normal bone when compared with the contralateral femur; grade 2 identifies the presence of asymmetric, radiolucent lesions limited to the distal femur; grade 3 identifies asymmetrical osteolytic destruction of the bone; and grade 4 identifies the presence of a pathological fracture of the bone or a breach in the bone cortex.
Micro-CT Imaging and Bone Density Quantitation
Computer tomography images were performed on anesthetized mice with a micro-CT scanner (ImTek, Knoxville, TN). Data were acquired at 70 ìm nomenial isotropic resolution voxel size with 196 projections, a photon energy of 40 keV, and a current of 350 A. The imaging acquisition time was 15 minutes per animal. A reconstruction algorithm supplied by ImTek (RVA3.8 combined with Cobra exxim 3.0.2) was used to reconstruct the raw data. For bone density quantitation, CT data obtained in .cst format were reformatted using Analyze 5.0 to allow the realignment of the femur in its entire length. Sixteenbit DICOM images from these reformatted data were then converted to a TIFF using Matlab 7.0.1. TIFF files were opened in Metamorph 6.2 for whole femur bone semi-quantitation measuring pixel area and data output to Excel (Microsoft, Redmond, WA) through dynamic data exchange (DDE).
Tumor Magnetic Resonance Imaging
All images were obtained on anesthetized mice using a 300-MHz Bruker BioSpin MRI (7.0 T) system (Bruker Instruments, Billerica, MA) equipped with a horizontal magnet. A 35-mm internal diameter linear birdcage resonator was used for radio frequency transmission and reception. Mice were placed in a specially designed holder that positioned their body horizontally with the leg at the isocenter of the birdcage resonator. Images were typically obtained over 25Y30 minutes. The Bruker T2 scanning protocol BRare_Mouse_Body^was used for imaging, with a TR/TE of 4567/36.2 ms, a slice thickness of 0.7 mm and a number of averages 4 rare factor 8. 
RESULTS
Quantification of Tumor Progression by Bioluminescence Imaging
The following first two experiments were performed to optimize the bioluminescence imaging parameters in our model and to standardize data acquisition. We initially performed a time course analysis of the light production by measuring bioluminescence every 6 minutes after the intraperitoneal (i.p.) injection of D-luciferin. This experiment demonstrated a maximal light production 18 minutes after injection of D-luciferin and a progressive decrease thereafter over 65 minutes. However, the bioluminescence production was maximal and relatively constant between 15 to 25 minutes providing a convenient Bwindow^for data acquisition (Fig. 1A) . In a second experiment we tested the effect of the positional angle of the leg on the bioluminescence acquisition by rotating the mouse over a longitudinal axis, leaving the distance between the mouse and the lens constant and only varying the angle of visualization. The data corrected for changes in signal over time (Fig. 1B) indicated no significant effect of rotation on light acquisition but an optimal recording at 30 degrees. On the basis of these data, image acquisition was performed 15 minutes after i.p. injection of D-luciferin at a 30-angle of rotation.
We next asked the question whether sequential bioluminescence imaging of the same animal over time could be used to monitor tumor progression in a quantitative manner. Five mice were injected with 2 Â 10 5 CHLA-255 luc WO1 cells into the right femur and imaged at 1 to 2 week intervals between week 2 and week 10 post injection of tumor cells. At the same time, mice were also radiographed to allow the comparison between tumor growth as measured by bioluminescence imaging and osteolytic bone remodeling as determined by radiographs. The data indicated a gradual increase in D-luciferin-based bioluminescence over the first 5 weeks, during which time grade 3 osteolytic changes were detected on radiographs ( Fig. 2A) . After 5 weeks however there was a rapid increase in D-luciferin-based bioluminescence that corresponded to the presence of grade 4 radiological lesions. In one mouse, 2 bioluminescent hot spots in the back were observed 11 weeks after injection of the tumor cells in the femur (Fig. 2B) , suggesting the presence of metastatic lesions to the kidneys or adrenal glands. In order to determine the exact location of these lesions, a gadolinium enhanced cross sectional MRI was done in vivo and indicated an involvement of the kidneys (Fig. 2C) . This was further confirmed by ex vivo D-luciferin-based bioluminescence and macroscopic examination of the kidney (Fig. 2D) .
We then tested whether sequential in vivo bioluminescence imaging of the same animal could provide a quantitative measure to monitor the effect of zoledronic acid, an inhibitor of osteolysis, on tumor progression. Among the effects of bisphosphonates is their ability to promote cell apoptosis by interfering with the mevalonate pathway and with protein prenylation. 15 This apoptotic effect is not restricted to osteoclasts and at micromolar concentrations bisphosphonates have been shown to induce apoptosis in tumor cells. 16 We therefore asked the question whether bioluminescence imaging could be used to measure in vivo the anti-tumor effect of zoledronic acid in our model. Six treated and 7 untreated mice injected with 2 Â 10 5 CHLA-255 luc WO1 cells into the right femur were examined by weekly radiographs and D-luciferin-based bioluminescence. Bone degradation as evaluated by radiographs (Fig. 3A to C) showed a predictable increase in osteolysis over 10 weeks from grade 1 at week 2 to 3, to grade 2 by week 4, grade 3 at week 5 to 7 and grade 4 by week 8 to 12 in the untreated group. In contrast, zoledronic acid-treated mice had radiological images of grade 1 and 2 and never developed grade 3 or 4 lesions. Analysis of progression by bioluminescence indicated a significant inhibition of D-luciferin-based luminescence between week 8 and 12, when the average luminescence in the treated group was significantly lower than the average luminescence in the untreated group (Fig. 3D , P = 0.003Y0.07). The rate of increase in the bioluminescence was also slower in the treatment group between week 8 and 10. The data are consistent with a direct anti-tumor effect of zoledronic acid and demonstrate that the analysis of D-luciferin-based bioluminescence provides a reliable quantitative method to monitor tumor progression in our model and to evaluate the antitumoral activity of agents that inhibit tumor-induced bone resorption.
Quantification of Bone Resorption by CT Imaging
The radiographic grading system developed allows only a semi-quantitative analysis of bone resorption. We therefore developed a quantitative method to measure the amount of bone loss over time in our model using micro-CT. In contrast to radiographs, which only provide 2D images, micro-CT offers the advantage of generating 3D images that can be readily processed to yield quantification of the data. We first developed a methodology to generate density distribution curves from images generated on the entire femoral bone in a living mouse not injected with tumor cells. The imaging experiment covered the lower half of the mouse body including both femurs and used a 512 Â 512 Â 512 matrix with a 36.86 mm cubic FOV. A first challenge was to generate images aligned with the longitudinal axis of the femur in its entire length from the femoral head to the condyles (Fig. 4A ). Mice were placed with their femurs aligned as close as possible to the imaging. The raw data generated (16 bit signed integers ImTeK .cst) were then loaded into Analyze 5.0, and the femurs were then rotated to the desired axis, to resample the data. Using this approach, we were able to generate images in which the femurs were accurately aligned parallel to the imaging plane (Fig. 4B) . These images were then cropped to include only the femur, saved in a 16 bit unsigned DICOM format and subsequently converted to TIFF using a Matlab 7.0.1 script. In Metamorph 6.0.1 the femurs were segmented out using a semi-automated routine, which required manual tracing near the ends of the bone. We then selected a cross-sectional area, which contained no trabecular bone in the middle of the femur to delineate the local threshold (Fig. 4C) . Every data set was analyzed using this methodology. The range of corrections for the local threshold was small with an average of 1312 T 132.8 with a typical data set having values ranging from j500 to +1300 (relative to bone set to 0). Each pixel in every segmented femur was assigned a density relative to the reference area (bone marrow cavity). Upon inspection of all the data, pixels with a relative density index above 300 were defined as bone and their lower limit was accordingly reset to 0. Using this thresholding methodology allowed us to delineate bone in each cross-sectional image of the femur without further user intervention (Fig. 4D ). Typically 240 cross-sections (slices) were then generated and analyzed over the length of a femur (Fig. 4E) . The distribution of pixels (according to their density index) was then plotted using data for the entire femur (Fig. 4F) . A sigmoidal distribution of pixels over density index range was observed with a progressive lower number of pixels with higher density index values.
In order to determine whether this analysis could measure loss of cortical bone during neoplastic invasion, we performed a sequential analysis by micro-CT of mice injected with CHLA-255 luc WO1 cells. This analysis revealed a progressive left shift with a decrease in the number of pixels with high density index values over time as the mice developed osteolytic lesions (Fig. 5A) . Interestingly, a significant shift in the curve with a decrease in the number of pixels with high density index values was documented between week 2 and week 3, when little osteolytic changes were radiographically detected (all radiograph readings were grade 2). An analysis of the data not only revealed a specific loss of pixels with high density index values but also a loss in the total number of pixels assigned as bone, indicating a loss in the total amount of mineralized bone over time (Fig. 5B) . We also tested the validity of our method by comparing measurements performed 10 weeks after injection of tumor cells in mice untreated and treated with zoledronic acid. This analysis indicated, as anticipated, a curve with a lower amount of pixels with high-density index values in untreated mice (control) and an increase in pixels with higher density index values in mice treated with zoledronic acid when compared with untreated mice (Fig. 5C ). This inhibition of bone resorption by zoledronic acid was confirmed by radiographs (Fig. 5D ).
Magnetic Resonance Imaging
We designed experiments to test the ability to generate MR images with sufficient resolution and contrast to detect tumor growth within the bone marrow cavity and at the early stages before evidence of cortical breach of the bone. We reasoned that because mice have little fat, the commonly used fat-saturated sequences would not be required. 17 We selected and tested a T2 Rare Sequence for its ability to provide short imaging times with optimal bone marrow and muscle to tumor contrast. The T1 weighted sequence while providing good resolution showed images with a low contrast. An optimized version of a standard Bruker T2 RARE weighted sequence (TR/TE 4567/36.2 ms rare factor 8 and 4 averages, in-plane 156 Km Â 234 Km and 700 Km slice thickness, 5 minutes acquisition) generated high-resolution images with a good separation between tumor and bone marrow or muscle in short imaging times. Data from one mouse imaged five times between day 38 and day 64 are shown in Figure 6 . At day 38 (Fig. 6A) axial T-weighted images containing both femurs revealed the presence of tumor cells starting to protrude outside the bone at the base of the femur head (4 Â magnification of right leg). The tumor tissue was hyper intense compared to normal bone marrow. At day 41 (Fig. 6B ) the image plane was taken parallel to the axis of the bone (sagittal plane) and the tumor cells could be easily distinguished from bone marrow and the muscle as they filled the bone shaft and started to grow outside the bone. At day 64 a coronal image with corresponding 4 Â magnification of the head of both femurs revealed an intensive destruction of the cortical bone and invasion of the tumor cells into adjacent muscles (Fig. 6C) .
DISCUSSION
Preclinical animal models play a critical role in our understanding of fundamental pathological processes and in the testing of drugs for their ability to alter these processes. High resolution imaging techniques have recently revolutionized our approach in using these models by allowing us to monitor sequentially in the same animal, the progression of a specific pathological condition and how it can be altered by therapeutic intervention. 18 These methods also provide more quantitative and reproducible measurements. Here we show that by combining radiographs, bioluminescence, micro-CT imaging, and micro-MRI it is possible to sequentially and quantitatively monitor tumor progression and bone resorption and evaluate the effect of agents interfering with bone invasion.
The use of enhanced green fluorescent protein (EGFP) or luciferase expressing tumor cells to determine and monitor their fate in metastatic murine tumor models has been rapidly expanding over the last several years. 19 Whole body optical imaging of mice injected into the tail vein of immunodeficient mice with EGFP expressing colon cancer cells allows monitoring the development of distant metastases in real time in specific organs like the liver and skeleton. 20 Because of its higher wavelength, higher tissue penetrance, and because it does not require an excitory light source, the luminescence emitted by luciferase-based expression systems has rapidly become the preferred method to monitor the metastatic behavior of malignant cells in preclinical murine models. 21, 22 Here we demonstrate that D-luciferin-induced bioluminescence is a highly sensitive method for the detection of intraosseous tumor lesions and that the measurement of the emitted bioluminescence over time under well defined conditions accurately reflects tumor load in the bone as well as the effect of an inhibitory agent like zoledronic acid. It also allows the sensitive detection of distant metastasis as demonstrated by the identification of kidney metastasis.
Recent advances in micro-CT system for in vivo imaging in small animals have also revolutionized the field and it is now possible to perform high-resolution measurement of bones to characterize the 3D architecture of trabecular bone. 23 Such high resolution scans however require relatively high doses of radiation. For this reason, the highest resolution studies have generally been done ex vivo with instruments specially designed for such studies. Imaging which accurately reflects trabecular bone architecture usually requires resolutions of at least 35 Km. 24, 25 These highly detailed studies require careful attention to the details of the post processing methodologies and are done almost exclusively ex vivo. 24 In vivo based studies, of which this study is an example, use lower resolutions than ex vivo studies, which usually preclude high resolution images of the trabecular bone. Higher resolution in vivo studies require a newest generation of scanners. 24 Using the slightly lower resolution by our scanner, we could not obtain fine architectural details of the trabecular bone and focused on cortical bone and on bone density. Using such a method we were able to evaluate in vivo bone density changes in an entire mouse femur based on a bone density index plotted versus number of pixels. The fact that the entire femur was used simplified the analysis by not requiring alignment of individual areas from examination to examination. The resulting plots contained all the data from approximately 240 slices through the femur obtained at 70 Km resolution in individual treated or untreated mice at specific time points along the progression of the disease. The methodology used existing software packages without the need of programming expertise and could be easily transferable to other laboratories. We demonstrated that such measurements detect loss in bone density at a very early stage of cancer invasion, when minimal radiographic changes are seen. Because we were primarily interested in quantifying relative changes in bone density in mice over time we made no attempt to perform absolute quantification of bone density.
Radiographs (with Faxitron instruments), Micro-CT and dual energy X-ray absorbance (DEXA) have been recently used to examine the effect of bisphosphonates including zoledronic acid in rodent models of arthritis, 26 myeloma 27 or mammary carcinoma bone metastasis. 28 These studies have shown that these imaging methods are helpful to determine and monitor the inhibitory effect of bisphosphonates. Quantification of the imaging data in vivo has however remained difficult and exact measurement of mineral densities of the trabecular as well as the cortical bone has required an ex vivo analysis. 28 Although limited to the cortical bone, our method allows to quantify the effect of bisphosphonates on bone mineralization in vivo, permitting therefore repeated determinations in the same animal over time.
MR imaging of bone lesions, involving either the bone marrow, bone or both is quite common in the clinical setting to follow a variety of pathologies such as bone cancer, 29 metastatic cancers, 30 and osteoarthritis. 31 Clinically T1-weighted spin echo images are the main MR sequences used to evaluate these lesions. Other sequences including T2-weighted and inversion recovery have been used. High resolution micro-MRI has proven useful in the study of bone, alone 32 and in combination with micro-CT. 33Y35 The use of MRI technology, however, has not been extensively explored in mouse models. High resolution MR imaging in general is not a practical method to screen for systemic lesions but proves to be most useful to examine a specific area of the body where a pathological process is occurring. We used it here to obtain high resolution images of the head of the femur or the kidneys that were initially identified as areas of tumor involvement by bioluminescence. MR imaging is primarily a soft tissue technique and bone generally produces little signal. However here by optimizing a T2 based technique we were able to follow tumor invasion inside the bone with high resolution (200Y300 Km) using short (5Y10 minutes) imaging times.
Our study demonstrates that by using multimodal imaging, several biological aspects of bone invasion by cancer cells can be examined in a more efficient manner. Whereas bioluminescence allowed us to detect the presence of metastases, MR imaging defined better the precise location and characteristics of these metastatic lesions. By combining micro-CT imaging of the bone with bioluminescence, it was possible to separately evaluate bone resorption and tumor growth. In addition, data generated through these techniques demonstrated that zoledronic acid treatment stops bone degradation while tumor growth continues, although at a slower rate. Although the data presented here have used invasive neuroblastoma cells as a model, it is anticipated that a similar imaging approach will be equally valuable and informative in models of myeloma, breast cancer or prostate cancer that metastasize to the bone. Furthermore, the methodology developed to quantify bone resorption by micro-CT may prove applicable to other conditions associated with increased bone resorption such as osteoarthritis or osteoporosis.
